Concepedia

Stefan Knackmuss

SK

23

Publications

1.6K

Citations

23

H-Index

2002

Active since

Affiliations

Affimed Therapeutics (Germany)(Current)

University of the Witwatersrand

German Cancer Research Center

Heidelberg University

Ludwig-Maximilians-Universität München

Stefan Knackmuss is an author at Affimed Therapeutics (Germany) specializing in medicine, cell biology, and immunology.

Top concepts

Publications per year

2002–2021

23

Publications

23

A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma

Achim Rothe, Stephanie Sasse, Max S. Topp et al. · Blood · 2015 · 320 citations · Full text

A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30<sup>+</sup>tumor cells

Uwe Reusch, Carmen Burkhardt, Ivica Fucek et al. · mAbs · 2014 · 158 citations · Full text

, , +18

A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19<sup>+</sup>tumor cells

Uwe Reusch, Johannes Duell, Kristina Ellwanger et al. · mAbs · 2015 · 125 citations · Full text

, , +17

Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies

Matthias Eder, Björn Wängler, Stefan Knackmuss et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2008 · 102 citations

, , +6

Synergistic Antitumor Effect of Bispecific CD19 × CD3 and CD19 × CD16 Diabodies in a Preclinical Model of Non-Hodgkin’s Lymphoma

Sergey M. Kipriyanov, Björn Cochlovius, Holger Schäfer et al. · The Journal of Immunology · 2002 · 90 citations · Full text

Rows per page

1–5 of 23